Malignant pleural effusion from lung adenocarcinoma treated by gefitinib

Akihito Kubo, Yasuhiro Koh, Tomoya Kawaguchi, Shun Ichi Isa, Isamu Okamoto, Junya Fukuoka, Yoko Kusunoki, Masanori Kitaichi, Minoru Takada, Kazuhiko Nakagawa

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Small molecule inhibitors targeting epidermal growth factor receptor (EGFR) are known to be active against non-small cell lung cancer (NSCLC) although the pharmacodynamics of these agents on malignant pleural effusion (MPE) remains unclear. Here we describe a case of lung adenocarcinoma with massive MPE treated successfully by gefitinib and chest drainage. Using sequential MPE samples before and during gefitinib therapy, the morphological changes and apoptosis of cancer cells were analyzed. Apoptosis of cancer cells was detected as early as 4 hours on, but not before, gefitinib therapy, suggesting that the pharmacodynamic assessment of such molecular targeting agents might be feasible for MPE.

Original languageEnglish
Pages (from-to)745-748
Number of pages4
JournalInternal Medicine
Volume50
Issue number7
DOIs
Publication statusPublished - 2011

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Fingerprint Dive into the research topics of 'Malignant pleural effusion from lung adenocarcinoma treated by gefitinib'. Together they form a unique fingerprint.

  • Cite this

    Kubo, A., Koh, Y., Kawaguchi, T., Isa, S. I., Okamoto, I., Fukuoka, J., Kusunoki, Y., Kitaichi, M., Takada, M., & Nakagawa, K. (2011). Malignant pleural effusion from lung adenocarcinoma treated by gefitinib. Internal Medicine, 50(7), 745-748. https://doi.org/10.2169/internalmedicine.50.4652